Soligenix Reports Positive Phase 2a Extension Results for Psoriasis Treatment SGX302
TL;DR
Soligenix's SGX302 offers a noncarcinogenic photodynamic therapy advantage for psoriasis, potentially capturing market share with its well-tolerated, first-in-class treatment.
SGX302 uses visible light-activated synthetic hypericin in an optimized gel formulation, applied twice weekly over 18 weeks with no drug-related adverse events reported.
This therapy provides a safer, noncarcinogenic treatment option for psoriasis patients, improving quality of life through an enhanced patient experience and clinical efficacy.
SGX302 introduces a novel photodynamic therapy using synthetic hypericin activated by visible light, representing an innovative approach to treating skin conditions.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (NASDAQ: SNGX) announced extended top-line results from its Phase 2a clinical trial of SGX302 for mild-to-moderate psoriasis, reporting the investigational therapy was well-tolerated with no drug-related adverse events in the extension cohort. The company's updated findings highlight clinical improvements with an optimized gel formulation, positioning SGX302 as a potential noncarcinogenic photodynamic treatment option for patients with this chronic autoimmune condition.
The Phase 2a trial progressed into an extension cohort that enrolled four additional patients treated with an improved topical gel formulation of SGX302. According to the company, the optimized gel was designed to improve patient experience with both easier dispensation and skin application. Patients applied SGX302 gel to psoriasis lesions twice weekly over an 18-week treatment period, mirroring the duration of prior study phases.
SGX302 utilizes visible light-activated synthetic hypericin, representing a first-in-class photodynamic therapy mechanism. This approach differs significantly from conventional psoriasis treatments that often carry carcinogenic risks or require systemic administration. The therapy's mechanism involves applying synthetic hypericin topically to affected areas, followed by activation with visible light, potentially offering localized treatment without systemic side effects.
The importance of these findings lies in addressing the substantial unmet medical need in psoriasis treatment, where many current options present safety concerns or limited efficacy. Psoriasis affects millions worldwide, causing not only physical symptoms but significant psychological and social burdens. A noncarcinogenic topical treatment that demonstrates good tolerability could represent a meaningful advancement in dermatological care, particularly for patients who cannot tolerate or have failed existing therapies.
For the biotechnology industry, Soligenix's progress with SGX302 demonstrates continued innovation in photodynamic therapies and rare disease treatment development. The company focuses on developing products for rare diseases where unmet medical need exists, and positive results in psoriasis could validate their approach to other conditions. Investors and industry observers can find additional information in the company's newsroom at https://ibn.fm/SNGX.
The potential impact extends beyond immediate clinical applications, as successful development of SGX302 could influence treatment paradigms for other dermatological conditions. The optimized gel formulation's improved patient experience factors could enhance treatment adherence, a critical consideration in chronic conditions requiring long-term management. As the therapy advances through clinical development, it may offer patients a new option that balances efficacy with safety considerations that are paramount in chronic disease management.
Curated from InvestorBrandNetwork (IBN)
